fomesafen has been researched along with Depression, Involutional in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chalaye, P; Marchand, S; Potvin, S; Tikàsz, A; Tourjman, V | 1 |
Bang-Andersen, B; Boyle, NJ; Brennum, LT; Bundgaard, C; Fischer, CW; Hogg, S; Lassen, AB; Liebenberg, N; Miller, S; Mørk, A; Nielsen, SM; Pehrson, A; Sánchez, C; Stensbøl, TB; Wegener, G; Westrich, L; Zhong, H | 1 |
Fitzgerald, PB; Georgiou-Karistianis, N; Millist, L; White, OB; Winograd-Gurvich, C | 1 |
Barnett, W; Fritzsche, M; Richter, P; Sattler, HD; von Turner, A | 1 |
Hádlík, J; Misurec, J; Náhunek, K; Rodová, A; Vanýsek, J | 1 |
2 trial(s) available for fomesafen and Depression, Involutional
Article | Year |
---|---|
Neurophysiologic tests during antidepressive treatment - an exploratory study.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Autonomic Nervous System; Depressive Disorder, Major; Doxepin; Female; Fluvoxamine; Heart Rate; Humans; Male; Middle Aged; Neural Conduction; Paroxetine; Psychometrics; Reaction Time; Reflex; Selective Serotonin Reuptake Inhibitors | 2000 |
[Comparison of triperidol with perphenazine in schizophrenic psychoses. Effect on the photomyoclonic threshold].
Topics: Adolescent; Adult; Antidepressive Agents; Butyrophenones; Clinical Trials as Topic; Depressive Disorder, Major; Female; Fluorine; Humans; Light; Male; Middle Aged; Myoclonus; Perphenazine; Piperidines; Placebos; Reflex; Schizophrenia; Trifluperidol | 1970 |
3 other study(ies) available for fomesafen and Depression, Involutional
Article | Year |
---|---|
Increased spinal pain sensitization in major depressive disorder: A pilot study.
Topics: Adult; Central Nervous System Sensitization; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Nociception; Pain Measurement; Reflex | 2016 |
Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder.
Topics: Animals; Anti-Anxiety Agents; Biogenic Monoamines; Citalopram; Depressive Disorder, Major; Humans; Male; Ondansetron; Piperazines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Reflex; Serotonin Plasma Membrane Transport Proteins; Sulfides; Vocalization, Animal; Vortioxetine | 2012 |
Ocular motor differences between melancholic and non-melancholic depression.
Topics: Adult; Cognition Disorders; Depressive Disorder; Depressive Disorder, Major; Diagnosis, Differential; Female; Humans; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Psychomotor Disorders; Reaction Time; Reflex; Saccades | 2006 |